≥ 1 point improvement on INCAT disability score at 12 months · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone may leads to higher ≥ 1 point improvement on INCAT disability score at 12 months compared with oral prednisolone (low certainty).
1 finding from 1 review
Change in MRC sum score · patients with chronic inflammatory demyelinating polyradiculoneuropathy
1 finding from 1 review
Complete remission (no further aphthous episodes to 6 months) · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 6 months: complete remission compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Treatment response at 6 months: partial remission · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 6 months: partial remission compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Complete or partial remission · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 6 months: complete or partial remission compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Treatment response at 18 months ‐ Sustained remission/steroid sensitive relapses Clinical assessment · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 18 months: sustained… compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Treatment response at 18 months ‐ CKD clinical assessment · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 18 months: CKD compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Adverse events: hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide may leads to lower adverse events: hypertension compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Adverse effects ‐ Bacterial infection clinical assessment · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in adverse events: bacterial infections compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Exacerbations · Adults with acute asthma
It is very uncertain whether adults: prednisolone changes new exacerbation during compared with dexamethasone (very low certainty).
2 findings from 1 review
Admission to hospital at initial presentation · children with acute asthma
Children: prednisolone showed no clear difference in admission at initial presentation compared with dexamethasone (low certainty).
1 finding from 1 review
Re‐admission during · children with acute asthma
Children: prednisolone showed no clear difference in re‐admission during compared with dexamethasone (low certainty).
1 finding from 1 review
Asthma symptoms · children with acute asthma
2 findings from 1 review
Serious adverse events · children with acute asthma
1 finding from 1 review
Exacerbations · children with acute asthma
Children: prednisolone showed no clear difference in new exacerbation during compared with dexamethasone (low certainty).
1 finding from 1 review
Re‐admission during · Adults with acute asthma
It is very uncertain whether adults: prednisolone changes re‐admission during compared with dexamethasone (very low certainty).
1 finding from 1 review
Asthma symptoms Returned to normal activities within 3 days · Adults with acute asthma
Adults: prednisolone showed no clear difference in asthma symptoms Returned to normal activities within 3 days compared with dexamethasone (low certainty).
1 finding from 1 review